<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02397083</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0944</org_study_id>
    <secondary_id>NCI-2015-00919</secondary_id>
    <secondary_id>2014-0944</secondary_id>
    <nct_id>NCT02397083</nct_id>
  </id_info>
  <brief_title>Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer</brief_title>
  <official_title>Phase II Study of the Levonorgestrel Intrauterine Device Alone or in Combination With the mTORC1 Inhibitor, Everolimus, for the Treatment of Complex Atypical Hyperplasia and Stage Ia Grade 1 Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well levonorgestrel-releasing intrauterine system&#xD;
      works when given alone or with everolimus in treating patients with atypical hyperplasia (a&#xD;
      pre-cancerous growth of the lining of the uterus) or stage IA grade 1 endometrial cancer. The&#xD;
      levonorgestrel-releasing intrauterine system is designed to prevent pregnancy by releasing a&#xD;
      hormone called levonorgestrel, which is a type of progesterone. Progesterone is a common type&#xD;
      of hormone that is used to prevent pregnancy and may prevent or slow tumor cell growth.&#xD;
      Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell&#xD;
      growth. It is not yet known whether the levonorgestrel-releasing intrauterine system works&#xD;
      better with or without everolimus in treating patients with atypical hyperplasia or stage IA&#xD;
      grade 1 endometrial cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Estimate the efficacy of the levonorgestrel intrauterine device (LIUD)&#xD;
      (levonorgestrel-releasing intrauterine system) alone to treat complex atypical hyperplasia or&#xD;
      stage Ia grade 1 endometrioid endometrial carcinoma with response rate.&#xD;
&#xD;
      II. Estimate the efficacy of the LIUD in combination with everolimus to treat LIUD-refractory&#xD;
      complex atypical hyperplasia or stage Ia grade 1 endometrioid endometrial carcinoma with&#xD;
      response rate.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Document the toxicity profile of the levonorgestrel intrauterine device alone or in&#xD;
      combination with everolimus using the National Institutes of Health-National Cancer Institute&#xD;
      (NIH-NCI) Common Terminology Criteria for Adverse Events version (v) 4.0.&#xD;
&#xD;
      II. Estimate overall survival (OS) and event-free survival (EFS) of patients with complex&#xD;
      atypical hyperplasia or stage Ia grade 1 endometrioid endometrial cancer treated with the&#xD;
      levonorgestrel IUD alone or in combination with everolimus.&#xD;
&#xD;
      III. Estimate the response duration associated with the levonorgestrel IUD alone or in&#xD;
      combination with everolimus in patients with complex atypical hyperplasia or stage Ia grade 1&#xD;
      endometrioid endometrial cancer.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. Determine if response to therapy can be predicted based on the molecular profile of the&#xD;
      tumor, including estrogen-induced genes and relevant pathway members, or by change in gene&#xD;
      expression after therapy.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      First Stage&#xD;
&#xD;
        -  If D&amp;C confirms EEC grade 1 or CAH-patient enrolled&#xD;
&#xD;
        -  If the patient is found to have stable disease at 3 months continue on to the second&#xD;
           stage of the study to be randomized.&#xD;
&#xD;
        -  If the patient has a complete response at 3 months; EMB 3 months later to confirm&#xD;
           complete response.&#xD;
&#xD;
        -  Once complete response confirmed, patient Continues EMB every 6-12 months until disease&#xD;
           progression per provider.&#xD;
&#xD;
        -  If the patient has progressive disease at 3 months- OFF STUDY Second Stage&#xD;
&#xD;
        -  Patients with stable disease at and 3 month EMB, recurrent disease at a subsequent EMB,&#xD;
           or entering protocol with outside IUD in place showing stable disease demonstrating&#xD;
           progesterone resistance&#xD;
&#xD;
      LIUD Only Arm&#xD;
&#xD;
        -  Visits every 3 months&#xD;
&#xD;
        -  EMB at 6 months&#xD;
&#xD;
        -  if regression/SD: continue on study&#xD;
&#xD;
        -  EMB at 9 months and 1 year:&#xD;
&#xD;
        -  Off study for PD or D&amp;C at MD's discretion&#xD;
&#xD;
        -  SD at 1 year: off study&#xD;
&#xD;
        -  CR at 1 year: SOC EMB 3 months later then Q6 months if confirmed CR&#xD;
&#xD;
        -  If continuing on study: Q6mo EMB until progression, D&amp;C, or pt./provider decision&#xD;
&#xD;
      LIUD+Everolimus Arm&#xD;
&#xD;
        -  If progression at cycle 3, 6, 9:&#xD;
&#xD;
        -  Discontinue everolimus, patient taken off study&#xD;
&#xD;
        -  CR at cycle 9:&#xD;
&#xD;
        -  EMB to confirm response at cycle 12&#xD;
&#xD;
        -  If response confirmed -EMB every 6 cycles (6 months)&#xD;
&#xD;
        -  Continue evaluations on each cycle day 1&#xD;
&#xD;
        -  SD at cycle 9:&#xD;
&#xD;
        -  Discontinue everolimus, come off study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2015</start_date>
  <completion_date type="Anticipated">September 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (levonorgestrel intrauterine device [LIUD] alone)</measure>
    <time_frame>At 3 months</time_frame>
    <description>Estimated with a 2-sided 90% confidence interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate (levonorgestrel intrauterine device [LIUD] alone)</measure>
    <time_frame>6 months</time_frame>
    <description>Estimated with a 2-sided 90% confidence interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate for levonorgestrel intrauterine device (LIUD) alone or in combination with everolimus after LIUD failure (i.e., failure to achieve complete response after initial 3 months of LIUD alone)</measure>
    <time_frame>6 months</time_frame>
    <description>Fisher's exact test will be used to compare response rates by 6 months between the LIUD alone arm and the LIUD plus everolimus arm. Estimated on each arm with a 2-sided 90% confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 11 years</time_frame>
    <description>Tabulated by treatment arm, severity, and relationship to study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 11 years</time_frame>
    <description>Estimated using the Kaplan-Meier product-limit estimator. The log-rank test will be used to compare treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 11 years</time_frame>
    <description>Estimated using the Kaplan-Meier product-limit estimator. The log-rank test will be used to compare treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>Up to 4 weeks after completion of study treatment</time_frame>
    <description>Estimated using the Kaplan-Meier product-limit estimator. The log-rank test will be used to compare treatment arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Atypical Endometrial Hyperplasia</condition>
  <condition>FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma</condition>
  <condition>FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (LIUD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients continue treatment with the LIUD for up to 9 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (LIUD, everolimus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients continue treatment with the LIUD and receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (LIUD, everolimus)</arm_group_label>
    <other_name>42-O-(2-Hydroxy)ethyl Rapamycin</other_name>
    <other_name>Afinitor</other_name>
    <other_name>Certican</other_name>
    <other_name>RAD 001</other_name>
    <other_name>RAD001</other_name>
    <other_name>Votubia</other_name>
    <other_name>Zortress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (LIUD)</arm_group_label>
    <arm_group_label>Arm II (LIUD, everolimus)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Levonorgestrel-Releasing Intrauterine System</intervention_name>
    <description>Placed in the uterus</description>
    <arm_group_label>Arm I (LIUD)</arm_group_label>
    <arm_group_label>Arm II (LIUD, everolimus)</arm_group_label>
    <other_name>Mirena</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with a diagnosis of complex atypical hyperplasia OR, grade 1 endometrioid&#xD;
             OR focal grade 2 adenocarcinoma in predominately grade 1 disease endometrial carcinoma&#xD;
             on endometrial biopsy or dilation and curettage (D &amp; C) within three months of study&#xD;
             enrollment&#xD;
&#xD;
          -  Patients with complex atypical hyperplasia OR grade 1 endometrioid adenocarcinoma with&#xD;
             stable/persistent disease with LIUD already in place. LIUD must have been in place for&#xD;
             at least 3 months&#xD;
&#xD;
          -  Prior progesterone treatment is ALLOWED, but a 28 day washout period is required&#xD;
             before LIUD placement. If archival tissue is available from prior to any progesterone&#xD;
             treatment, the washout period is not needed&#xD;
&#xD;
          -  Ability to comply with endometrial biopsies every 3 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelets &gt;= 100 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin (Hb) &gt; 9 g/dL&#xD;
&#xD;
          -  Total serum bilirubin =&lt; 2.0 mg/dL&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 2.5 x upper&#xD;
             limit of normal (ULN)&#xD;
&#xD;
          -  International normalized ratio (INR) =&lt; 2; factor 10A drawn if patient on&#xD;
             anticoagulant Eliquis&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Fasting serum cholesterol =&lt; 300 mg/dL OR =&lt; 7.75 mmol/L AND fasting triglycerides =&lt;&#xD;
             2.5 x ULN; NOTE: in case one or both of these thresholds are exceeded, the patient can&#xD;
             only be included after initiation of appropriate lipid lowering medication&#xD;
&#xD;
          -  Signed informed consent obtained prior to any screening procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with grade 2-3 endometrioid, uterine serous, clear cell, mucinous, squamous,&#xD;
             transitional cell, sarcomas, or carcinosarcoma histology&#xD;
&#xD;
          -  Evidence of extrauterine spread of disease on imaging or during surgical evaluation&#xD;
&#xD;
          -  Patients who have prior therapy with everolimus or any other mammalian target of&#xD;
             rapamycin (mTOR) inhibitor&#xD;
&#xD;
          -  Patients currently receiving anticancer therapies (including chemotherapy, radiation&#xD;
             therapy, hormonal, or antibody-based therapy); prior treatment should have a washout&#xD;
             period of 28 days or 4 1/2 half-lives (7 days), whichever is shorter&#xD;
&#xD;
          -  Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g.&#xD;
             sirolimus, temsirolimus)&#xD;
&#xD;
          -  Known intolerance or hypersensitivity to progesterone or its excipients&#xD;
&#xD;
          -  Known impairment of gastrointestinal (GI) function or GI disease that may&#xD;
             significantly alter the absorption of oral everolimus (e.g., inability to take oral&#xD;
             medication or a requirement for intravenous [IV] alimentation, prior surgical&#xD;
             procedures affecting absorption, malabsorption syndrome, and active peptic ulcer&#xD;
             disease) are excluded; subjects with ulcerative colitis, inflammatory bowel disease,&#xD;
             or a partial or complete small bowel obstruction are also excluded, as are any&#xD;
             patients who cannot swallow the capsule whole&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus as defined by glycosylated hemoglobin (HbA1c) &gt; 8%&#xD;
             despite adequate therapy; patients with a known history of impaired fasting glucose or&#xD;
             diabetes mellitus (DM) may be included, however blood glucose and antidiabetic&#xD;
             treatment must be monitored closely throughout the trial and adjusted as necessary&#xD;
&#xD;
          -  Patients who have any severe and/or uncontrolled medical conditions such as: a)&#xD;
             unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction&#xD;
             =&lt; 6 months prior to start of everolimus, serious uncontrolled cardiac arrhythmia, or&#xD;
             any other clinically significant cardiac disease; b) symptomatic congestive heart&#xD;
             failure of New York Heart Association class III or IV; c) active (acute or chronic) or&#xD;
             uncontrolled severe infection (not responding to antibiotics), liver disease such as&#xD;
             cirrhosis, decompensated liver disease, and active and chronic hepatitis (i.e.&#xD;
             quantifiable hepatitis B virus-deoxyribonucleic acid [HBV-DNA] and/or positive&#xD;
             hepatitis B surface antigen [HbsAg], quantifiable hepatitis C virus-ribonucleic acid&#xD;
             [HCV-RNA]); d) known severely impaired lung function (spirometry and diffusing&#xD;
             capacity of the lung for carbon monoxide [DLCO] 50% or less of normal and oxygen [O2]&#xD;
             saturation 88% or less at rest on room air); e) active, bleeding diathesis&#xD;
&#xD;
          -  Chronic treatment with corticosteroids or other immunosuppressive agents; topical or&#xD;
             inhaled corticosteroids are allowed&#xD;
&#xD;
          -  Patients who have a known history of human immunodeficiency virus (HIV) seropositivity&#xD;
&#xD;
          -  Patients who have received live attenuated vaccines within 1 week of start of&#xD;
             everolimus and during the study; patient should also avoid close contact with others&#xD;
             who have received live attenuated vaccines; examples of live attenuated vaccines&#xD;
             include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus&#xD;
             Calmette-Guerin (BCG), yellow fever, varicella and TY21a typhoid vaccines&#xD;
&#xD;
          -  Other malignancies within the past 3 years except for basal or squamous cell carcinoma&#xD;
             of the skin&#xD;
&#xD;
          -  Active (acute or chronic) or uncontrolled severe infections (not responding to&#xD;
             antibiotics), including acute pelvic inflammatory disease&#xD;
&#xD;
          -  Congenital or acquired uterine anomaly which distorts the uterine cavity&#xD;
&#xD;
          -  Genital actinomycosis&#xD;
&#xD;
          -  Patients with a history of non-compliance to medical regimens or who are considered&#xD;
             potentially unreliable or will not be able to complete the entire study&#xD;
&#xD;
          -  Patients who are currently part of or have participated in any clinical investigation&#xD;
             with an investigational drug within 1 month prior to dosing&#xD;
&#xD;
          -  Women who are pregnant or nursing (lactating) women&#xD;
&#xD;
          -  Women of child-bearing potential (WOCBP), defined as women physiologically capable of&#xD;
             becoming pregnant, must use one additional highly effective methods of contraception&#xD;
             in addition to the LIUD during the study and 8 weeks after; acceptable effective&#xD;
             contraception methods include combo of the following: a) barrier methods of&#xD;
             contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with&#xD;
             spermicidal foam/gel/film/cream/ vaginal suppository; b) total abstinence or; c)&#xD;
             male/female sterilization; women are considered post-menopausal and not of&#xD;
             child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea&#xD;
             with an appropriate clinical profile (e.g. age appropriate, history of vasomotor&#xD;
             symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy)&#xD;
             or tubal ligation &gt; six weeks prior to randomization; in the case of oophorectomy&#xD;
             alone, only when the reproductive status of the woman has been confirmed by follow up&#xD;
             hormone level assessment is she considered not of child-bearing potential&#xD;
&#xD;
          -  Women who are on contraindicated medications to everolimus must have confirmation from&#xD;
             their physician that they may change or discontinue the medication if randomized to&#xD;
             the LIUD + everolimus arm&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shannon N Westin</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shannon Westin</last_name>
    <phone>713-794-4314</phone>
    <email>swestin@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>North Colorado Medical Center</name>
      <address>
        <city>Greeley</city>
        <state>Colorado</state>
        <zip>80631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin A. Lacour</last_name>
      <email>robin.lacour@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Robin A. Lacour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McKee Medical Center</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin A. Lacour</last_name>
      <email>robin.lacour@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Robin A. Lacour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Keith Y. Terada</last_name>
      <phone>808-526-2477</phone>
      <email>kterada@ucera.org</email>
    </contact>
    <investigator>
      <last_name>Keith Y. Terada</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Health Network Inc</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46254</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael W. Method</last_name>
      <email>mmethod@ecommunity.com</email>
    </contact>
    <investigator>
      <last_name>Michael W. Method</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Covenant HealthCare Mackinaw</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory P. Sutton</last_name>
      <email>gregory.sutton@chs-mi.com</email>
    </contact>
    <investigator>
      <last_name>Gregory P. Sutton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Berkeley Heights</city>
        <state>New Jersey</state>
        <zip>07922</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Darlene G. Gibbon</last_name>
      <email>gibbonda@cinj.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Darlene G. Gibbon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cooper Hospital University Medical Center</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David P. Warshal</last_name>
      <phone>855-632-2667</phone>
      <email>warshal-david@cooperhealth.edu</email>
    </contact>
    <investigator>
      <last_name>David P. Warshal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OhioHealth Mansfield Hospital</name>
      <address>
        <city>Mansfield</city>
        <state>Ohio</state>
        <zip>44903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aine E. Clements</last_name>
      <email>aine.clements@ohiohealth.com</email>
    </contact>
    <investigator>
      <last_name>Aine E. Clements</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Memorial City Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole D. Fleming</last_name>
      <phone>713-792-3245</phone>
      <email>nfleming@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Nicole D. Fleming</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lyndon Baines Johnson General Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77026-1967</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Onstad</last_name>
      <phone>713-745-7418</phone>
      <email>maonstad@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Michaela Onstad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon N. Westin</last_name>
      <phone>713-794-4314</phone>
    </contact>
    <investigator>
      <last_name>Shannon N. Westin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Woman's Hospital of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael W. Bevers</last_name>
      <email>mbevers@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Michael W. Bevers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson in Katy</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael W. Bevers</last_name>
      <email>mbevers@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Michael W. Bevers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson League City</name>
      <address>
        <city>Nassau Bay</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Behrouz Zand</last_name>
      <phone>713-563-4367</phone>
      <email>BZand@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Behrouz Zand</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christus Santa Rosa Hospital-Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georgia A. McCann</last_name>
      <phone>210-567-3406</phone>
      <email>mccanng@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Georgia A. McCann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson in Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole D. Fleming</last_name>
      <phone>713-792-3245</phone>
      <email>nfleming@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Nicole D. Fleming</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson in The Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren P. Cobb</last_name>
      <phone>713-745-8511</phone>
      <email>lpcobb@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Lauren P. Cobb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari L. Ring</last_name>
      <email>kel7j@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Kari L. Ring</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
    <mesh_term>Endometrial Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

